Printed from https://ideas.repec.org/s/spr/pharme8.html
Content
March 2012, Volume 30, Issue 3
- 247-256 Rufinamide
by Paul McCormack
February 2012, Volume 30, Issue 2
- 83-86 Health Utility Elicitation
by Lisa Prosser & Scott Grosse & Eve Wittenberg - 87-101 Cost Effectiveness of Rivaroxaban versus Enoxaparin for Prevention of Post-Surgical Venous Thromboembolism from a US Payer’s Perspective
by Aurea Duran & Nishan Sengupta & Alexander Diamantopoulos & Fiona Forster & Louis Kwong & Michael Lees - 103-118 Granulocyte-Colony Stimulating Factor Use and Medical Costs after Initial Adjuvant Chemotherapy in Older Patients with Early-Stage Breast Cancer
by Robert Griffiths & Richard Barron & Michelle Gleeson & Mark Danese & Anthony O’Hagan & Victoria Chia & Jason Legg & Gary Lyman - 119-126 Incorporating Calibrated Model Parameters into Sensitivity Analyses
by Douglas Taylor & Vivek Pawar & Denise Kruzikas & Kristen Gilmore & Myrlene Sanon & Milton Weinstein - 127-131 Why Not Real Economics?
by F. Reed Johnson - 133-136 Real Economics Needs to Reflect Real Decisions
by Mark Sculpher & Karl Claxton - 137-146 Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Hip or Knee Surgery
by Michael Holmes & Christopher Carroll & Diana Papaioannou - 147-170 Osteoporotic Fractures
by Sangeeta Budhia & Yeshi Mikyas & Michael Tang & Enkhe Badamgarav
January 2012, Volume 30, Issue 1
- 1-16 Economic and Humanistic Burden of External Genital Warts
by Adam Raymakers & Mohsen Sadatsafavi & Fawziah Marra & Carlo Marra - 17-34 Cost Effectiveness of Treatment with New Agents in Advanced Non-Small-Cell Lung Cancer
by Mathilda Bongers & Veerle Coupé & Elise Jansma & Egbert Smit & Carin Groot - 35-46 Dronedarone for the Treatment of Atrial Fibrillation
by Claire McKenna & Emma Maund & Muhammad Sarowar & David Fox & Matt Stevenson & Chris Pepper & Nerys Woolacott & Stephen Palmer - 47-61 Does the EQ-5D Reflect Lost Earnings?
by Carl Tilling & Marieke Kro & Aki Tsuchiya & John Brazier & Job Exel & Werner Brouwer - 63-80 A Systematic Review of the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant Tuberculosis
by Christopher Fitzpatrick & Katherine Floyd - 81-81 Erratum to Systematic Reviewof the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant Tuberculosis
by C. Fitzpatrick & K. Floyd
December 2011, Volume 29, Issue 12
- 1014-1014 Erratum to: The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK
by Á Benedict & L Verdian & G Maclaine - 1015-1023 QALYs and Carers
by Hareth Al-Janabi & Terry Flynn & Joanna Coast - 1025-1049 Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease
by Judith Dams & Bernhard Bornschein & Jens Reese & Annette Conrads-Frank & Wolfgang Oertel & Uwe Siebert & Richard Dodel - 1063-1073 Cost-Effectiveness Analysis of Prophylactic Lamivudine Use in Preventing Vertical Transmission of Hepatitis B Virus Infection
by Hui-Fang Hung & Hsiu-Hsi Chen - 1075-1091 Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective
by Helen Dakin & Morris Sherman & Scott Fung & Carrie Fidler & Anthony Bentley
November 2011, Volume 29, Issue 11
- 933-949 Sample Size Determination for Cost-Effectiveness Trials
by Andrew Willan - 963-975 Willingness to Pay for Adverse Drug Event Regulatory Actions
by Jacoline Bouvy & Just Weemers & Huub Schellekens & Marc Koopmanschap - 977-988 Patient Benefit-Risk Preferences for Targeted Agents in the Treatment of Renal Cell Carcinoma
by Ateesha Mohamed & A. Hauber & Maureen Neary - 989-1009 Rotavirus Vaccine RIX4414 (Rotarix™)
by Greg Plosker
October 2011, Volume 29, Issue 10
- 839-861 A Review of the Costs and Cost Effectiveness of Interventions in Chronic Kidney Disease
by Joseph Menzin & Lisa Lines & Daniel Weiner & Peter Neumann & Christine Nichols & Lauren Rodriguez & Irene Agodoa & Tracy Mayne - 875-882 Does the Market Share of Generic Medicines Influence the Price Level?
by Pieter Dylst & Steven Simoens
September 2011, Volume 29, Issue 9
- 781-806 Economic Evaluation of Policy Options for Prevention and Control of Cervical Cancer in Thailand
by Naiyana Praditsitthikorn & Yot Teerawattananon & Sripen Tantivess & Supon Limwattananon & Arthorn Riewpaiboon & Saibua Chichareon & Nantakan Ieumwananonthachai & Viroj Tangcharoensathien
August 2011, Volume 29, Issue 8
- 653-671 Cost-of-Illness Studies
by Allison Larg & John Moss - 693-704 Cost Estimation of Cardiovascular Disease Events in the US
by Amy O’Sullivan & Jaime Rubin & Joshua Nyambose & Andreas Kuznik & David Cohen & David Thompson
July 2011, Volume 29, Issue 7
- 555-561 Prioritizing Comparative Effectiveness Research
by Afschin Gandjour - 563-577 Presenting Evidence and Summary Measures to Best Inform Societal Decisions When Comparing Multiple Strategies
by Simon Eckermann & Andrew Willan - 579-599 Unit Costs for Delivery of Antiretroviral Treatment and Prevention of Mother-to-Child Transmission of HIV
by Omar Galárraga & Veronika Wirtz & Alejandro Figueroa-Lara & Yared Santa-Ana-Tellez & Ibrahima Coulibaly & Kirsi Viisainen & Antonieta Medina-Lara & Eline Korenromp - 601-619 Do Productivity Costs Matter?
by Marieke Krol & Jocé Papenburg & Marc Koopmanschap & Werner Brouwer - 621-635 Medication Costs to Private Insurers of Diversion of Medications for Attention-Deficit Hyperactivity Disorder
by Arnie Aldridge & Larry Kroutil & Alexander Cowell & Daniel Reeves & David Brunt
May 2011, Volume 29, Issue 5
- 414-414 Erratum to: Cost Effectiveness of Budesonide/Formoterol Added to Tiotropium Bromide versus Placebo Added to Tiotropium Bromide in Patients with Chronic Obstructive Pulmonary Disease
by Nicole Mittmann & Paul Hernandez & Carl Mellström & Lance Brannman & Tobias Welte
April 2011, Volume 29, Issue 4
- 287-296 Sample Size and Power for Cost-Effectiveness Analysis (Part 2)
by Henry Glick
March 2011, Volume 29, Issue 3
- 189-198 Sample Size and Power for Cost-Effectiveness Analysis (Part 1)
by Henry Glick - 199-211 Cost Effectiveness of Pneumococcal Conjugate Vaccination against Acute Otitis Media in Children
by Chantal Boonacker & Pieter Broos & Elisabeth Sanders & Anne Schilder & Maroeska Rovers - 239-250 Comparing Methods of Data Synthesis
by Mark Oppe & Maiwenn Al & Maureen Rutten-Mölken
February 2011, Volume 29, Issue 2
- 107-131 Cost Effectiveness of Treatments for Wet Age-Related Macular Degeneration
by Paul Mitchell & Lieven Annemans & Richard White & Meghan Gallagher & Simu Thomas
January 2011, Volume 29, Issue 1
- 1-15 Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis
by Martin Hoyle - 17-33 Effects of Reference Pricing in Pharmaceutical Markets
by Matteo Galizzi & Simone Ghislandi & Marisa Miraldo - 35-49 Calibrating Models in Economic Evaluation
by Tazio Vanni & Jonathan Karnon & Jason Madan & Richard White & W. Edmunds & Anna Foss & Rosa Legood - 51-62 Calibrating Models in Economic Evaluation
by Jonathan Karnon & Tazio Vanni - 63-82 Availability of and Access to Orphan Drugs
by Carl Blankart & Tom Stargardt & Jonas Schreyögg - 83-84 Is There a Role for Pharmacoeconomics in Developing Countries?
by Asrul Shafie & Mohamed Hassali - 84-86 The Authors’ Reply
by Zaheer-Ud-Din Babar & Shane Scahill
December 2010, Volume 28, Issue 12
- 1109-1121 A Review and Critique of Studies Reporting Utility Values for Schizophrenia-Related Health States
by Ifigeneia Mavranezouli
November 2010, Volume 28, Issue 11
- 987-993 An Analysis of NICE’s ‘Restricted’ (or ‘Optimized’) Decisions
by Phill O’Neill & Nancy Devlin - 995-1000 Methods of Model Calibration
by Douglas Taylor & Vivek Pawar & Denise Kruzikas & Kristen Gilmore & Ankur Pandya & Rowan Iskandar & Milton Weinstein - 1001-1013 Cost Effectiveness of Pharmacogenomics
by William Wong & Josh Carlson & Rahber Thariani & David Veenstra - 1025-1039 Economic Efficiency of Genetic Screening to Inform the Use of Abacavir Sulfate in the Treatment of HIV
by Teresa Kauf & Raymond Farkouh & Stephanie Earnshaw & Maria Watson & Penny Maroudas & Mike Chambers - 1041-1054 Economic Evaluation of Cinacalcet in the Treatment of Secondary Hyperparathyroidism in Italy
by Mario Eandi & Lorenzo Pradelli & Sergio Iannazzo & Silvia Chiroli & Giuseppe Pontoriero - 1055-1064 Cost Effectiveness of Imiquimod 5% Cream Compared with Methyl Aminolevulinate-Based Photodynamic Therapy in the Treatment of Non-Hyperkeratotic, Non-Hypertrophic Actinic (Solar) Keratoses A Decision Tree Model
by Edward Wilson
October 2010, Volume 28, Issue 10
- 813-830 International Comparison of Comparative Effectiveness Research in Five Jurisdictions
by Adrian Levy & Craig Mitton & Karissa Johnston & Brian Harrigan & Andrew Briggs - 877-887 Comparative Effectiveness Regulations and Pharmaceutical Innovation
by John Vernon & Joseph Golec & J. Stevens - 915-922 Comparative Effectiveness Research
by Marc Berger & David Grainger - 935-945 Comparative Effectiveness Without Head-to-Head Trials
by James Signorovitch & Eric Wu & Andrew Yu & Charles Gerrits & Evan Kantor & Yanjun Bao & Shiraz Gupta & Parvez Mulani - 957-967 No Head-to-Head Trial? Simulate the Missing Arms
by J.Jaime Caro & K. Ishak
September 2010, Volume 28, Issue 9
- 711-722 Using Conjoint Analysis and Choice Experiments to Estimate QALY Values
by Terry Flynn - 751-764 Cost Effectiveness of Adjunctive Quetiapine Fumarate Extended-Release Tablets with Mood Stabilizers in the Maintenance Treatment of Bipolar I Disorder
by Tatia Woodward & Eskinder Tafesse & Peter Quon & Arthur Lazarus - 765-780 An Economic Evaluation of Colesevelam when Added to Metformin-, Insulinor Sulfonylurea-Based Therapies in Patients with Uncontrolled Type 2 Diabetes Mellitus
by W. Simons & Michael Hagan
August 2010, Volume 28, Issue 8
- 615-628 Financial Effects of Pharmaceutical Price Regulation on R&D Spending by EU versus US Firms
by Joseph Golec & John Vernon - 675-685 Economic Burden of Epilepsy among the Privately Insured in the US
by Jasmina Ivanova & Howard Birnbaum & Yohanne Kidolezi & Ying Qiu & David Mallett & Sue Caleo
July 2010, Volume 28, Issue 7
- 521-538 Cost Effectiveness of Venous Thromboembolism Pharmacological Prophylaxis in Total Hip and Knee Replacement
by Alok Kapoor & Warren Chuang & Nila Radhakrishnan & Kenneth Smith & Dan Berlowitz & Jodi Segal & Jeffrey Katz & Elena Losina - 539-553 The State of Health Economic Evaluation Research in Nigeria
by Paul Gavaza & Karen Rascati & Abiola Oladapo & Star Khoza - 585-595 Cost Effectiveness of Leukotriene Receptor Antagonists versus Inhaled Corticosteroids for Initial Asthma Controller Therapy
by Edward Wilson & Erika Sims & Stanley Musgrave & Lee Shepstone & Annie Blyth & Jamie Murdoch & H. Mugford & Elizabeth Juniper & Jon Ayres & Stephanie Wolfe & Daryl Freeman & Richard Gilbert & Ian Harvey & Elizabeth Hillyer & David Price - 597-608 Cost Effectiveness of Leukotriene Receptor Antagonists versus Long-Acting Beta-2 Agonists as Add-On Therapy to Inhaled Corticosteroids for Asthma
by Edward Wilson & David Price & Stanley Musgrave & Erika Sims & Lee Shepstone & Jamie Murdoch & H. Mugford & Annie Blyth & Elizabeth Juniper & Jon Ayres & Stephanie Wolfe & Daryl Freeman & Richard Gilbert & Elizabeth Hillyer & Ian Harvey
June 2010, Volume 28, Issue 6
- 463-475 Are Cancer Drugs Less Likely to be Recommended for Listing by the Pharmaceutical Benefits Advisory Committee in Australia?
by Lesley Chim & Patrick Kelly & Glenn Salkeld & Martin Stockler - 477-487 Understanding the Relationship between the EQ-5D, SF-6D, HAQ and Disease Activity in Inflammatory Arthritis
by Roisin Adams & Cathal Walsh & Douglas Veale & Barry Bresnihan & Oliver FitzGerald & Michael Barry - 489-505 Cost Effectiveness of 5-Alpha Reductase Inhibitors for the Prevention of Prostate Cancer in Multiple Patient Populations
by Stephanie Earnshaw & Cheryl McDade & Libby Black & Christopher Bell & Michael Kattan - 507-520 Does the Inclusion of a Cost Attribute Result in Different Preferences for the Surgical Treatment of Primary Basal Cell Carcinoma?
by Brigitte Essers & Debby Helvoort-Postulart & Martin Prins & Martino Neumann & Carmen Dirksen
May 2010, Volume 28, Issue 5
- 381-393 Health Economic Burden of Patients with Restless Legs Syndrome in a German Ambulatory Setting
by Richard Dodel & Svenja Happe & Ines Peglau & Geert Mayer & Jürgen Wasem & Jens-Peter Reese & Guido Giani & Max Geraedts & Claudia Trenkwalder & Wolfgang Oertel & Karin Stiasny-Kolster - 395-409 Direct and Indirect Costs of Non-Vertebral Fracture Patients with Osteoporosis in the US
by Crystal Pike & Howard Birnbaum & Matt Schiller & Hari Sharma & Russel Burge & Eric Edgell - 411-427 Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimer’s Disease
by Denis Getsios & Steve Blume & K. Ishak & Grant Maclaine - 429-438 Economic Content in Medical Journal Advertisements for Medical Devices and Prescription Drugs
by D. Ackerly & Seth Glickman & Kevin Schulman
March 2010, Volume 28, Issue 3
- 185-199 The Cost Effectiveness of Rufinamide in the Treatment of Lennox-Gastaut Syndrome in the UK
by Ágnes Benedict & Lara Verdian & Grant Maclaine
January 2010, Volume 28, Issue 1
- 35-46 Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma
by Eric Deconinck & Houda Miadi-Fargier & Claude Pen & Pauline Brice - 47-60 Cost Effectiveness of Intensive Lipid-Lowering Treatment for Patients with Congestive Heart Failure and Coronary Heart Disease in the US
by Virginia Rosen & Douglas Taylor & Hemangi Parekh & Ankur Pandya & David Thompson & Andreas Kuznik & David Waters & Michael Drummond & Milton Weinstein - 61-74 A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing
by Lisa Meckley & James Gudgeon & Jeffrey Anderson & Marc Williams & David Veenstra
December 2009, Volume 27, Issue 12
- 991-1004 Cost Effectiveness of Herpes Zoster Vaccine in Canada
by Mehdi Najafzadeh & Carlo Marra & Eleni Galanis & David Patrick - 1005-1016 Willingness to Pay for a QALY Based on Community Member and Patient Preferences for Temporary Health States Associated with Herpes Zoster
by Tracy Lieu & G. Ray & Ismael Ortega-Sanchez & Ken Kleinman & Donna Rusinak - 1017-1029 Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical Trials
by Aline Gauthier & Andrea Manca & Susan Anton
November 2009, Volume 27, Issue 11
- 903-917 Cost Effectiveness in Low- and Middle-Income Countries
by Samuel Shillcutt & Damian Walker & Catherine Goodman & Anne Mills - 919-929 Barriers to Generalizability of Health Economic Evaluations in Latin America and the Caribbean Region
by Federico Augustovski & Cynthia Iglesias & Andrea Manca & Michael Drummond & Adolfo Rubinstein & Sebastián Martií
October 2009, Volume 27, Issue 10
- 797-806 Economic Evaluation and Cost-Effectiveness Thresholds
by John Vernon & Robert Goldberg & Joseph Golec - 873-886 Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective
by Peng Liubao & Wan Xiaomin & Tan Chongqing & Jon Karnon & Chen Gannong & Li Jianhe & Cui Wei & Luo Xia & Cao Junhua
August 2009, Volume 27, Issue 8
- 635-643 Estimating Drug Costs in Economic Evaluations in Ireland and the UK
by Dyfrig Hughes & Lesley Tilson & Michael Drummond - 657-679 Economic Burden of Follicular Non-Hodgkin’s Lymphoma
by Talia Foster & Jeffrey Miller & Mark Boye & Mason Russell
July 2009, Volume 27, Issue 7
- 533-545 Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines
by Natasha Stout & Amy Knudsen & Chung Kong & Pamela McMahon & G. Gazelle - 609-621 Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn’s Disease
by Andrew Yu & Scott Johnson & Si-Tien Wang & Pavel Atanasov & Jackson Tang & Eric Wu & Jingdong Chao & Parvez Mulani
May 2009, Volume 27, Issue 5
- 355-363 The Future Costs, Risks and Rewards of Drug Development
by Joseph Cook & Graeme Hunter & John Vernon - 391-403 The Cost of Dementia in Europe
by Linus Jönsson & Anders Wimo - 405-419 Utility Assessment in Patients with Mental Disorders
by Hans-Helmut König & Oliver Günther & Matthias Angermeyer & Christiane Roick
April 2009, Volume 27, Issue 4
- 267-279 Economic and Human Costs of Restless Legs Syndrome
by Thomas Reinhold & Falk Müller-Riemenschneider & Stefan Willich & Bernd Brüggenjürgen - 281-297 Reviewing the Cost Effectiveness of Rotavirus Vaccination
by Joke Bilcke & Philippe Beutels - 313-327 Cost Effectiveness of Drug-Eluting Stents In Belgian Practice
by Mattias Neyt & Chris Laet & Annemieke Ridder & Hans Brabandt - 329-339 Impact of Transdermal Oxybutynin on Work Productivity in Patients with Overactive Bladder
by Laura Pizzi & Amy Talati & Eric Gemmen & Naomi Dahl & Thomas Bunz & Peter Sand
March 2009, Volume 27, Issue 3
- 221-230 The Lifetime Cost Effectiveness of Amlodipine-Based Therapy Plus Atorvastatin Compared with Atenolol Plus Atorvastatin, Amlodipine-Based Therapy Alone and Atenolol-Based Therapy Alone
by Peter Lindgren & Martin Buxton & Thomas Kahan & Neil Poulter & Björn Dahlöf & Peter Sever & Hans Wedel & Bengt Jönsson - 231-245 Cost-Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium
by Lieven Annemans & Vanessa Rémy & James Oyee & Nathalie Largeron - 247-261 Cost-Utility Analysis of Varenicline, an Oral Smoking-Cessation Drug, in Japan
by Ataru Igarashi & Hiroki Takuma & Takashi Fukuda & Kiichiro Tsutani
February 2009, Volume 27, Issue 2
- 91-93 Controlling Cervical Cancer
by Maurizio Bonati & Silvio Garattini - 95-112 Neuropathic Pain
by Alec O’Connor - 127-147 Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine
by Fawziah Marra & Karine Cloutier & Bridgette Oteng & Carlo Marra & Gina Ogilvie - 159-165 Comparison of Markov Model and Discrete-Event Simulation Techniques for HIV
by Kit Simpson & Alvin Strassburger & Walter Jones & Birgitta Dietz & Rukmini Rajagopalan
January 2009, Volume 27, Issue 1
- 25-37 Statin Therapy in Rheumatoid Arthritis
by Nick Bansback & Roberta Ara & Sue Ward & Aslam Anis & Hyon Choi - 55-68 Cost Effectiveness of High-Dose Chemotherapy with Autologous Stem Cell Support as Initial Treatment of Aggressive Non-Hodgkin’s Lymphoma
by Philippe Fagnoni & Noel Milpied & Samuel Limat & Eric Deconinck & Virginie Nerich & Charles Foussard & Philippe Colombat & Jean-Luc Harousseau & Marie-Christine Woronoff-Lemsi - 81-90 Estimating the Cost of Diabetes Mellitus-Related Events from Inpatient Admissions in Sweden Using Administrative Hospitalization Data
by Ulf-G Gerdtham & Philip Clarke & Alison Hayes & Soffia Gudbjornsdottir
December 2008, Volume 26, Issue 12
- 1005-1017 Measuring US Pharmaceutical Industry R&D Spending
by Joseph Golec & John Vernon - 1019-1035 Management and Prevention of Diabetic Foot Ulcers and Infections
by Ivy Chow & Elkin Lemos & Thomas Einarson - 1045-1064 A Cost-Utility Comparison of Four First-Line Medications in Painful Diabetic Neuropathy
by Alec O’Connor & Katia Noyes & Robert Holloway
November 2008, Volume 26, Issue 11
- 911-924 The Impact of Influenza on Working Days Lost
by Martin Keech & Paul Beardsworth - 925-935 A Review of Health-Utility Data for Osteoarthritis
by Hirsch Ruchlin & Ralph Insinga - 937-949 A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B
by D. Spackman & David Veenstra - 951-967 Economic Impact and Long-Term Graft Outcomes of Mycophenolate Mofetil Dosage Modifications Following Gastrointestinal Complications in Renal Transplant Recipients
by Gerardo Machnicki & Jean-Francois Ricci & Daniel Brennan & Mark Schnitzler - 969-981 Escitalopram and Duloxetine in Major Depressive Disorder
by Alan Wade & José-Luis Fernández & Clément François & Karina Hansen & Natalya Danchenko & Nicolas Despiege
August 2008, Volume 26, Issue 8
- 649-659 Assessing the Impact of Global Price Interdependencies
by Anke Richter - 661-677 Conducting Discrete Choice Experiments to Inform Healthcare Decision Making
by Emily Lancsar & Jordan Louviere
July 2008, Volume 26, Issue 7
- 589-602 Future Drug Prices and Cost-Effectiveness Analyses
by Martin Hoyle - 603-616 Generic Entry, Reformulations and Promotion of SSRIs in the US
by Haiden Huskamp & Julie Donohue & Catherine Koss & Ernst Berndt & Richard Frank - 617-627 Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK
by Ray Gani & Gavin Giovannoni & David Bates & Belinda Kemball & Steve Hughes & John Kerrigan
June 2008, Volume 26, Issue 6
- 447-462 Economic Burden of Heart Failure in the Elderly
by Lawrence Liao & Larry Allen & David Whellan - 513-536 Cost Effectiveness of the German Screen-and-Treat Strategy for Postmenopausal Osteoporosis
by Dirk Mueller & Eva Weyler & Afschin Gandjour
April 2008, Volume 26, Issue 4
- 311-328 Cost Effectiveness of Ibandronate for the Prevention of Fractures in Inflammatory Bowel Disease-Related Osteoporosis
by Simon Kreck & Jochen Klaus & Reiner Leidl & Christian Tirpitz & Alexander Konnopka & Herbert Matschinger & Hans-Helmut König
March 2008, Volume 26, Issue 3
- 191-215 Cost-Effectiveness Analyses of Vaccination Programmes
by Sun-Young Kim & Sue Goldie - 217-234 Preferences of Patients with Diabetes Mellitus for Inhaled versus Injectable Insulin Regimens
by Jeremy Chancellor & Samuel Aballéa & Alison Lawrence & Rob Sheldon & Sandrine Cure & Juliette Plun-Favreau & Nick Marchant - 235-249 Community and Patient Values for Preventing Herpes Zoster
by Tracy Lieu & Ismael Ortega-Sanchez & G. Ray & Donna Rusinak & W. Yih & Peter Choo & Irene Shui & Ken Kleinman & Rafael Harpaz & Lisa Prosser
January 2008, Volume 26, Issue 1
- 17-32 Cost-Effectiveness Analyses of Hepatitis A Vaccine
by Andrea Anonychuk & Andrea Tricco & Chris Bauch & Ba’ Pham & Vladimir Gilca & Bernard Duval & Ava John-Baptiste & Gloria Woo & Murray Krahn - 33-44 Carmustine Implants for the Treatment of Newly Diagnosed High-Grade Gliomas
by Gabriel Rogers & Ruth Garside & Stuart Mealing & Martin Pitt & Rob Anderson & Matthew Dyer & Ken Stein & Margaret Somerville - 57-73 Economic Burden of Bilateral Neovascular Age-Related Macular Degeneration
by Alan Cruess & Gergana Zlateva & Xiao Xu & Gièle Soubrane & Daniel Pauleikhoff & Andrew Lotery & Jordi Mones & Ronald Buggage & Caroline Schaefer & Tyler Knight & Thomas Goss
December 2007, Volume 25, Issue 12
- 995-996 When NICE Says No!
by Alan Haycox - 997-1006 NICE Cost-Effectiveness Appraisal of Cholinesterase Inhibitors
by Denis Getsios & Kristen Migliaccio-Walle & Jaime Caro - 1007-1029 Recombinant Factor VIIa (Eptacog Alfa)
by Katherine Lyseng-Williamson & Greg Plosker - 1031-1053 Atorvastatin
by Greg Plosker & Katherine Lyseng-Williamson - 1055-1062 Economic Evidence at the Local Level
by Kees Gool & Gisselle Gallego & Marion Haas & Rosalie Viney & Jane Hall & Robyn Ward - 1063-1082 Oral Antiplatelet Therapy in Secondary Prevention of Cardiovascular Events
by Bart Heeg & Joep Damen & Ben Hout
November 2007, Volume 25, Issue 11
- 899-902 Warfarin Pharmacogenetics
by Dyfrig Hughes & Munir Pirmohamed - 903-911 It’s Time to Choose the Study Design!
by Oren Shavit & Moshe Leshno & Assaf Goldberger & Amir Shmueli & Amnon Hoffman - 913-933 The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis
by Rachael Fleurence & Cynthia Iglesias & Jeanene Johnson - 963-977 Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B
by David Veenstra & Sean Sullivan & Lauren Clarke & Uche Iloeje & Eskinder Tafesse & Adrian Bisceglie & Kris Kowdley & Robert Gish
October 2007, Volume 25, Issue 10
- 807-816 Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health Interventions
by Jeffrey Hoch & Carolyn Dewa - 829-841 A Comparison of the Cost Effectiveness of Pharmacotherapy or Surgery (Laparoscopic Fundoplication) in the Treatment of GORD
by Laura Bojke & Edward Hornby & Mark Sculpher - 843-862 Use of Bayesian Net Benefit Regression Model to Examine the Impact of Generic Drug Entry on the Cost Effectiveness of Selective Serotonin Reuptake Inhibitors in Elderly Depressed Patients
by Ya-Chen Shih & Nebiyou Bekele & Ying Xu - 863-879 Cost Effectiveness of Pegaptanib for the Treatment of Age-Related Macular Degeneration in the UK
by Sorrel Wolowacz & Neil Roskell & Steven Kelly & Fiona Maciver & Chris Brand - 881-897 Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections of Insulin
by Neale Cohen & Michael Minshall & Lyn Sharon-Nash & Katerina Zakrzewska & William Valentine & Andrew Palmer
September 2007, Volume 25, Issue 9
- 713-726 Measuring Health Preferences for Use in Cost-Utility and Cost-Benefit Analyses of Interventions in Children
by Lisa Prosser & James Hammitt & Ron Keren - 751-768 Epidemiology and Economic Impact of Meticillin-Resistant Staphylococcus aureus
by Andrew Shorr - 769-782 Long-Term Clopidogrel Therapy in Patients Receiving Percutaneous Coronary Intervention
by Bart Heeg & Ron Peters & Marc Botteman & Ben Hout
July 2007, Volume 25, Issue 7
- 577-590 A Cost-Effectiveness Analysis of First-Line Controller Therapies for Persistent Asthma
by Ya-Chen Shih & Josephine Mauskopf & Rohit Borker - 605-618 Direct and Indirect Costs Attributable to Alcohol Consumption in Germany
by Alexander Konnopka & Hans-Helmut König
June 2007, Volume 25, Issue 6
- 467-479 A Systematic Review of Economic Evaluation Literature in Thailand
by Yot Teerawattananon & Steve Russell & Miranda Mugford - 481-496 Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs
by Theodore Darkow & Henry Henk & Simu Thomas & Weiwei Feng & Jean-Francois Baladi & George Goldberg & Alan Hatfield & Jorge Cortes
May 2007, Volume 25, Issue 5
- 365-384 Health Utilities Using the EQ-5D in Studies of Cancer
by A. Pickard & Caitlyn Wilke & Hsiang-Wen Lin & Andrew Lloyd - 385-396 The Work Productivity and Activity Impairment Questionnaire for Patients with Gastroesophageal Reflux Disease (WPAI-GERD)
by Peter Wahlqvist & Gordon Guyatt & David Armstrong & Alessio Degl’Innocenti & Diane Heels-Ansdell & Samer El-Dika & Ingela Wiklund & Carlo Fallone & Lisa Tanser & Sander Zanten & Peggy Austin & Alan Barkun & Naoki Chiba & Holger Schünemann - 397-411 Costs of a Community Pharmacist-Led Medicines Management Service for Patients with Coronary Heart Disease in England
by Anthony Scott & Michela Tinelli & Christine Bond - 429-442 Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer
by J. Millar & Michael Millward
March 2007, Volume 25, Issue 3
- 209-221 Do Drugs Reduce Utilisation of Other Healthcare Resources?
by Pierre-Yves Crémieux & Pierre Ouellette & Patrick Petit - 223-237 Recombinant Erythropoietin for Chemotherapy-Related Anaemia
by Diego Ossa & Andrew Briggs & Emma McIntosh & Warren Cowell & Tim Littlewood & Mark Sculpher - 239-251 Cost Effectiveness of an Adherence-Improving Programme in Hypertensive Patients
by Danielle Brunenberg & Gwenn Wetzels & Patricia Nelemans & Carmen Dirksen & Johan Severens & Henri Stoffers & Jan Schouten & Martin Prins & Peter Leeuw & Manuela Joore
February 2007, Volume 25, Issue 2
- 93-106 Measuring Preferences for Cost-Utility Analysis
by Christine McDonough & Anna Tosteson - 155-169 Acute/Subacute Herpes Zoster
by Ralph Insinga & Robbin Itzler & James Pellissier
January 2007, Volume 25, Issue 1
- 1-2 Letter From the Commissioner’s Office at the US FDA
by John Vernon - 3-6 Rates and Probabilities in Economic Modelling
by Rachael Fleurence & Christopher Hollenbeak - 7-24 Reducing the Societal Burden of Depression
by Julie Donohue & Harold Pincus - 25-37 Cost Effectiveness of a Pharmacy-Based Coaching Programme to Improve Adherence to Antidepressants
by Judith Bosmans & Oscar Brook & Hein Hout & Martine Bruijne & Hugo Nieuwenhuyse & Lex Bouter & Wim Stalman & Maurits Tulder - 39-54 A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK
by Dominic Tilden & Segundo Mariz & Gillies O’Bryan-Tear & Julia Bottomley & Alexander Diamantopoulos - 55-71 Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children
by Mark Nuijten & Wolfgang Wittenberg & Maximilian Lebmeier - 73-88 Time Preferences for Health in Northern Tanzania
by Bjarne Robberstad & John Cairns
December 2006, Volume 24, Issue 12
- 1173-1177 Do Pharmacogenomic Tests Provide Value to Policy Makers?
by Ya-Chen Shih & Lajos Pusztai - 1179-1179 Letter From the Commissioner’s Office at the US FDA
by John Vernon - 1181-1197 Assessing Generalisability in Model-Based Economic Evaluation Studies
by Hege Urdahl & Andrea Manca & Mark Sculpher - 1199-1220 Generic Health-Related Quality-of-Life Assessment in Children and Adolescents
by Ulrike Ravens-Sieberer & Michael Erhart & Nora Wille & Ralf Wetzel & Jennifer Nickel & Monika Bullinger - 1221-1232 Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis
by James Spalding & Joel Hay - 1233-1248 Association of Co-Morbidities with Prescribing Patterns and Cost Savings
by Wei Yu & Xinhua Ren & Austin Lee & Lawrence Herz & Yu-Hui Huang & Lewis Kazis - 1249-1272 Candesartan Cilexetil
by Greg Plosker & Susan Keam - 1273-1274 Discounting Health Effects in Pharmacoeconomic Evaluations: Current Controversies
by Stuart Birks - 1275-1276 The Authors’ Reply
by J. Bos & M. Postma & L. Annemans
September 2006, Volume 24, Issue 9
- 833-836 US FDA Guidance
by Paul Kind - 837-844 Accuracy versus Transparency in Pharmacoeconomic Modelling
by David Eddy - 845-853 The Value of Thinly Spread QALYs
by Duncan Mortimer - 855-868 Using Discrete Choice Experiments within a Cost-Benefit Analysis Framework
by Emma McIntosh - 869-890 Cost-of-Illness Studies
by Ebere Akobundu & Jing Ju & Lisa Blatt & C. Mullins - 891-902 Impacts of Cost Containment Strategies on Pharmaceutical Expenditures of the National Health Insurance in Taiwan, 1996–2003
by Yue-Chune Lee & Ming-Chin Yang & Yu-Tung Huang & Chien-Hsiang Liu & Sun-Bing Chen - 903-915 Public Funding of Bosentan for the Treatment of Pulmonary Artery Hypertension in Australia
by John Wlodarczyk & Leslie Cleland & Anne Keogh & Keith McNeil & Kate Perl & Robert Weintraub & Trevor Williams - 917-925 Missing Data Imputation in Quality-of-Life Assessment
by Ting Lin - 927-929 Modelling Lifetime Metabolic Progression and Cost Effectiveness of Treatment Strategies for Type 2 Diabetes
by Andrew Palmer & Craig Currie - 929-935 The Authors’ Reply
by Adrian Bagust & Marc Evans & Sophie Beale & Philip Home & Andrew Perry & Murray Stewart & Arran Shearer & Alan Martin & Lisa Hulme & Andreas Liebl & Oliver Schoeffski & Anita Goertz & Javier Ampudia-Blasco & Belen Martinez-Lage & Isabel Escolano & Gonzalo Paris
August 2006, Volume 24, Issue 8
- 743-750 Prostaglandin Analogues for the Treatment of Glaucoma and Ocular Hypertension
by Michelle Orme & Annabel Boler - 751-765 A Comparative Review of Health-Related Quality-of-Life Measures for Use in HIV/AIDS Clinical Trials
by Darren Clayson & Diane Wild & Paul Quarterman & Isabelle Duprat-Lomon & Maria Kubin & Stephen Coons - 797-814 Costs of Inflammatory Bowel Disease in Germany
by Renee Stark & Hans-Helmut König & Reiner Leidl - 815-830 Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada
by Michele Kohli & Cheryl Attard & Annette Lam & Daniel Huse & John Cook & Chantal Bourgault & Evo Alemao & Donald Yin & Michael Marentette
June 2006, Volume 24, Issue 6
- 523-535 Pharmacoeconomics of Angiotensin II Antagonists in Type 2 Diabetic Patients with Nephropathy
by Cornelis Boersma & Jarir Atthobari & Ron Gansevoort & Lolkje Jong-Van den Berg & Paul Jong & Dick Zeeuw & Lieven Annemans & Maarten Postma - 537-548 Healthcare Rationing in Spain
by Rosa Rodríguez-Monguió & Fernando Villar - 549-558 The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy
by George Carides & Shahnaz Shahinfar & Erik Dasbach & William Keane & William Gerth & Charles Alexander & William Herman & Barry Brenner - 559-569 The Effects of Type 1 Diabetes and its Long-Term Complications on Physical and Mental Health Status
by Jarmo Hahl & Helena Hämäläinen & Tuula Simell & Olli Simell - 571-591 Cost Effectiveness of Enoxaparin as Prophylaxis against Venous Thromboembolic Complications in Acutely Ill Medical Inpatients
by Peter Schädlich & Michael Kentsch & Manfred Weber & Wolfgang Kämmerer & Josef Brecht & Vijay Nadipelli & Eduard Huppertz - 593-607 Dalteparin versus Warfarin for the Prevention of Recurrent Venous Thromboembolic Events in Cancer Patients
by George Dranitsaris & Mark Vincent & Mark Crowther - 609-621 Is the Childhood Asthma Questionnaire a Good Measure of Health-Related Quality of Life of Asthmatic Children in Asia?
by Lee-Yee Chong & Oh-Moh Chay & Li Shu-Chuen